Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGT | O15294 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | CFD | P00746 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 2/20 | 0.42 |
| ▸ | DDO | Q99489 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 6/20 | 0.39 |
| ▸ | HTR1A | P08908 | 5/20 | 0.39 |
| ▸ | PTDSS1 | P48651 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 3/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23790624 | 0.84 | GABRA1 (0.43) | OGTF2CFDGABRA1GABRB2 | |
| SCHEMBL27610690 | 0.84 | MCL1 (0.43) | OGTPTDSS1 | |
| SCHEMBL5542039 | 0.84 | OGT (0.44) | OGTF2CFDDRD2HTR1A | |
| SCHEMBL16172349 | 0.84 | F2 (0.46) | OGTF2CFDDAODDO | |
| SCHEMBL21334472 | 0.83 | OGT (0.41) | OGTF2CFDDRD2HTR1A | |
| SCHEMBL27039073 | 0.82 | SLC6A2 (0.43) | OGTF2CFDDRD2HTR1A | |
| SCHEMBL5546637 | 0.81 | OGT (0.42) | OGTF2CFDDRD2HTR1A | |
| SCHEMBL4509421 | 0.79 | F2 (0.49) | OGTF2CFDDAODDO | |
| SCHEMBL434293 | 0.79 | OGT (0.50) | OGTF2CFDDAODDO | |
| SCHEMBL5541370 | 0.78 | OGT (0.40) | OGTF2CFDDRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | OGT 3461/4885F2 1369/4885CFD 2234/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | OGT 2963/4885F2 1898/4885CFD 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.